Liver-Specific Nucleic Acid Regulatory Elements for Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy vectors face challenges with insufficient and transient transgene expression levels, inappropriate expression in unwanted cell types, and immune responses, limiting the efficacy and safety of liver-directed gene therapy, particularly due to the limited packaging capacity of AAV vectors and the need for higher vector doses that can trigger immune responses.
Innovation Solution
Identification and utilization of evolutionarily conserved transcription factor binding site motifs associated with highly expressed liver-specific genes, incorporated into nucleic acid regulatory elements to enhance liver-specific gene expression, allowing for lower and safer vector doses while maximizing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If higher vector doses are used to improve transgene expression levels, then expression efficacy is improved, but immune responses are triggered reducing safety
Solution Approach 1:
The patent changes the regulatory parameters of the vector by incorporating specific liver-specific regulatory elements (enhancers, promoters, polyadenylation sequences) to optimize transgene expression. This allows achieving high expression levels through improved regulatory sequence design rather than increasing vector dose, thereby avoiding immune responses.
Solution Approach 2:
The patent applies liver-specific regulatory elements that target gene expression specifically to hepatocytes. This localizes the high-level expression to the desired tissue (liver) while using lower overall vector doses, reducing systemic immune activation compared to non-specific high-dose delivery.
2Productivity
If vector packaging capacity is increased to include more regulatory elements, then expression control is improved, but vector design complexity increases
Solution Approach 1:
The patent divides the regulatory control into separate functional modules: liver-specific enhancers, promoters, and polyadenylation sequences. These modular elements can be independently selected and combined within the AAV vector packaging capacity to achieve optimal liver-specific expression without requiring a single complex regulatory region.
3Productivity
If transgene expression is increased to improve therapeutic effect, then therapeutic efficacy is improved, but inappropriate expression in unwanted cell types occurs
Solution Approach 1:
The patent changes the tissue-specificity parameter of transgene expression by incorporating liver-specific regulatory elements. The enhancers containing hepatocyte-specific transcription factor binding sites (e.g., HNF1α, HNF4α, C/EBP) ensure that high-level expression occurs only in hepatocytes, not in other cell types, thereby achieving therapeutic effect without off-target expression.
Data Source
AI summary
The present invention relates to nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy, more particularly liver-directed gene therapy, and for vaccination purposes.